Armistice Capital LLC Grows Stock Position in Cencora, Inc. $COR

Armistice Capital LLC increased its holdings in shares of Cencora, Inc. (NYSE:COR) by 298.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 28,000 shares of the company’s stock after buying an additional 20,967 shares during the period. Armistice Capital LLC’s holdings in Cencora were worth $9,457,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. AustralianSuper Pty Ltd acquired a new stake in shares of Cencora during the 3rd quarter valued at about $26,191,000. Lansforsakringar Fondforvaltning AB publ lifted its stake in Cencora by 5.4% in the 3rd quarter. Lansforsakringar Fondforvaltning AB publ now owns 60,254 shares of the company’s stock worth $18,831,000 after purchasing an additional 3,073 shares in the last quarter. Chilton Investment Co. Inc. purchased a new position in Cencora in the 3rd quarter worth approximately $459,000. Nordea Investment Management AB lifted its stake in Cencora by 3.8% in the 4th quarter. Nordea Investment Management AB now owns 1,256,356 shares of the company’s stock worth $426,715,000 after purchasing an additional 45,712 shares in the last quarter. Finally, Groupama Asset Managment purchased a new stake in shares of Cencora during the 3rd quarter valued at approximately $1,225,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently commented on COR shares. Morgan Stanley set a $342.00 price target on shares of Cencora in a research report on Friday, May 8th. Evercore set a $360.00 price target on shares of Cencora in a research note on Wednesday, April 8th. Citigroup dropped their price target on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. UBS Group boosted their target price on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Finally, Leerink Partners reiterated an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Twelve research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $374.00.

Cencora Trading Down 1.6%

NYSE COR opened at $277.10 on Thursday. The stock has a market capitalization of $53.91 billion, a P/E ratio of 21.25, a P/E/G ratio of 1.52 and a beta of 0.59. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54. The firm has a 50-day moving average price of $286.62 and a 200 day moving average price of $325.41. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same period in the prior year, the company earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities research analysts expect that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio is presently 18.40%.

Cencora announced that its board has approved a stock repurchase plan on Thursday, May 21st that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 3.9% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.